![](https://cdn.sanity.io/images/0vv8moc6/onclive/51cc9fcd70ad2805a51b6c18d8584398553937c6-200x200.webp?fit=crop&auto=format)
FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors
The FDA has granted fast track designation to the ex vivo gene-modified autologous CAR-monocyte therapy, CT-0525, for use as a potential therapeutic option in patients with HER2-overexpressing solid tumors.1 CT-0525 is based on CD14-positive monocytes that …